Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

(2021) Kevin Litchfield et al.   CELL

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects

(2021) Spyridoula Vasileiou et al.   JOURNAL OF CLINICAL ONCOLOGY

The Next Decade of Immune Checkpoint Therapy

(2021) Padmanee Sharma et al.   Cancer Discovery

Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy

(2021) Martin Thelen et al.   npj Precision Oncology

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

(2020) Paul J. Bröckelmann et al.   JAMA Oncology

Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58

(2020) Johanna Veldman et al.   BLOOD

Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma

(2020) Pamela Blair Allen et al.   BLOOD

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma

(2020) Jeffrey C Thompson et al.   Journal for ImmunoTherapy of Cancer

The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma

(2020) Joji Nagasaki et al.   Blood Advances

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

(2020) Sarah Reinke et al.   BLOOD

Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma

(2020) Layal El Halabi et al.   Clinical Lymphoma Myeloma & Leukemia

Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma

(2019) Jing Nie et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

(2019) Radhakrishnan Ramchandren et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

(2019) Yuqin Song et al.   LEUKEMIA

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative

(2019) Sanjay S. Patel et al.   BLOOD

Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma

(2019) Tomohiro Aoki et al.   Cancer Discovery

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

(2018) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

(2018) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity

(2018) Ludmila Danilova et al.   Cancer Immunology Research

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

(2018) Yelena Y. Janjigian et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction and transcriptional regulation of the co-inhibitory gene module in T cells

(2018) Norio Chihara et al.   NATURE

Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer

(2018) Nataly Manjarrez-Orduño et al.   Frontiers in Immunology

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

(2017) Bertrand Allard et al.   IMMUNOLOGICAL REVIEWS

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of responses to immune checkpoint blockade in advanced melanoma

(2017) N. Jacquelot et al.   Nature Communications

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

(2017) Marcel Nijland et al.   OncoImmunology

A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells

(2016) Meromit Singer et al.   CELL

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Targeting T Cell Co-receptors for Cancer Therapy

(2016) Margaret K. Callahan et al.   IMMUNITY

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

(2016) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma

(2015) Vehbi Ercolak et al.   ACTA HAEMATOLOGICA

Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells

(2014) J. Reichel et al.   BLOOD

Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein–Barr virus-specific T cells as targets of interest in immunotherapeutic approaches

(2014) Sabine Tischer et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens

(2013) N. Masque-Soler et al.   BLOOD

Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients

(2012) Riguel J. Inaoka et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma

(2011) Ulrike Gerdemann et al.   MOLECULAR THERAPY

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD